RECRUITING

Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to develop and evaluate the usefulness of MRI using 129Xe gas for regional assessment of pulmonary function. Specifically, three forms of 129Xe MRI contrast will be the investigators focus - 1) imaging of the 129Xe ventilation distribution, 2) imaging the alveolar microstructure via the 129Xe apparent diffusion coefficient (ADC), and 3) imaging 129Xe that dissolves in the pulmonary blood and tissues upon inhalation. Such imaging of 129Xe gas transfer is expected to be uniquely sensitive to pathologies affecting gas exchange (fibrosis, emphysema, pulmonary hypertension) and provide new insights regarding the normal resting heterogeneity of pulmonary gas exchange.

Official Title

Hyperpolarized 129Xe MR Imaging of the Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

Quick Facts

Study Start:2011-01
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01280994

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Subject has no diagnosed pulmonary conditions
  2. 2. Subject has not smoked in the previous 5 years.
  3. 3. Smoking history, if any, is less than or equal to 5 pack-years.
  4. 1. Subject has a diagnosis of pulmonary dysfunction made by a physician
  5. 2. No acute worsening of pulmonary function in the past 30 days
  1. 1. Subject is less than 18 years old
  2. 2. MRI is contraindicated based on responses to MRI screening questionaire
  3. 3. Subject is pregnant or lactating
  4. 4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI
  5. 5. Subject has received an investigational medicinal product (not including 129Xe) within 30 days of MRI
  6. 6. Subject has any form of known cardiac arrhythmia
  7. 7. Subject does not fit into 129Xe vest coil used for MRI
  8. 8. Subject cannot hold his/her breath for 15 seconds
  9. 9. Subject deemed unlikely to be able to comply with instructions during imaging

Contacts and Locations

Study Contact

Jennifer Korzekwinski
CONTACT
919-681-7362
jennifer.korzekwinski@duke.edu
Cody Blanton
CONTACT
919-668-7575
cody.blanton@duke.edu

Principal Investigator

Joseph Mammarappallil, M.D.
PRINCIPAL_INVESTIGATOR
Duke University

Study Locations (Sites)

Duke University Medical Center
Durham, North Carolina, 27710
United States

Collaborators and Investigators

Sponsor: Bastiaan Driehuys

  • Joseph Mammarappallil, M.D., PRINCIPAL_INVESTIGATOR, Duke University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2011-01
Study Completion Date2025-12

Study Record Updates

Study Start Date2011-01
Study Completion Date2025-12

Terms related to this study

Keywords Provided by Researchers

  • Lung Disease
  • Pulmonary Disease
  • Diagnostic Imaging
  • MRI

Additional Relevant MeSH Terms

  • Interstitial Lung Disease